



TO

All Providers, HMOs and Other Managed Care Programs

REGARDING

Reimbursement Resumed for Administration of Johnson & Johnson COVID-19 Vaccine

Reimbursement Resumed for Administration of Johnson & Johnson COVID-19 Vaccine

Effective for dates of service on and after April 27, 2021, **ForwardHealth has resumed reimbursement for administration of the Johnson & Johnson COVID-19 vaccine**, ending a reimbursement pause communicated in [Alert 037](#), titled "Reimbursement Paused for Administration of Johnson & Johnson COVID-19 Vaccine."

Johnson & Johnson COVID-19 vaccine administration reimbursement is allowed for dates of service:

- Beginning February 27, 2021, through April 12, 2021.
- On and after April 27, 2021.

Claims submitted for the paused dates of service will not be reimbursed.

The federal [Advisory Committee on Immunization Practices](#) and the Wisconsin Department of Health Services have cleared the Johnson & Johnson COVID-19 vaccine for continued use.

PROCEDURE CODE	DESCRIPTION
91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, single dose

Additional information is available on the federal [Advisory Committee on Immunization Practices webpage](#) and the [Wisconsin Department of Health Services webpage](#).

COVID-19-related ForwardHealth Alerts and Updates are available on the [COVID-19: ForwardHealth News and Resources](#) page of the ForwardHealth Portal.